Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

Goldman Sachs upgraded BioNTech (BNTX) to Buy from Neutral with a price target of $137, up from $90. The firm upgrade the shares after ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Last November, BioNTech (NASDAQ: BNTX) licensed BNT327 from a clinical-stage company called Biotheus. In a phase 2 trial, a ...

BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

This outlook is backed by the inclusion of risk-adjusted revenue forecasts for BioNTech's BNT323 and BNT327 in their valuation model. H.C. Wainwright's reiteration of the Buy rating along with the ...

In other recent news, BioNTech has been the subject of several analyst upgrades, with Jefferies changing its rating from Hold to Buy, citing the potential of the investigational drug BNT327, which ...